Standard operating procedure

Similar documents
Standard operating procedure

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products

Standard operating procedure

Title: Handling of a request for accelerated assessment of initial marketing authorisation applications (human use)

1 March 2010 EMA/131300/2010 Human Medicines Development and Evaluation. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom

Standard operating procedure

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Frequently asked questions

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Pharmacovigilance Working Party (PhVWP)

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

European Medicines Agency decision

Initial (Full) Marketing Authorisation application accelerated assessment timetables

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Product. Commission. Summary Notification 1. Information issued on. Decision. Issued 2 / affected 3 amended on

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS

Guidance on format of the risk management plan (RMP) in the EU part II: Module SIV - Populations not studied in clinical trials

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

The European Medicines Agency (EMA)

European Medicines Agency decision

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on

European Medicines Agency decision

European Medicines Agency decision

Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture

Paediatric Investigation Plans for treatment of osteoporosis

PRAC recommendations on signals

The European Medicines Agency (EMA)

European Medicines Agency decision

Discussion by HMPC Drafting Group on Quality February Start of public consultation 27 June 2012

Agreed by Gastroenterology Drafting Group May Adopted by CHMP for release for consultation 24 May Start of public consultation 8 June 2012

European Medicines Agency decision

Supporting regulatory science outside the EU. The Article 58 procedure. An agency of the European Union

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015

STANDARD OPERATING PROCEDURE

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

European Medicines Agency decision

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

European Medicines Agency recommends changes to the use of metoclopramide

Suspected Defective Product Report

Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 18/08/2017 SmPC and PL. 24/05/2017 SmPC, Annex II, Labelling

European Medicines Agency decision

Update on public hearing

Centralized Procedure

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias

Pandemic report and lessons learned

European Medicines Agency decision

European Medicines Agency decision

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

European Medicines Agency decision

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 08/03/2018 n/a

STANDARD OPERATING PROCEDURE SOP 720 RISK ASSESSMENT OF TRIALS SPONSORED. BY THE NNUH and UEA

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Inventory of paediatric therapeutic needs

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Overview of the Procedure and interactions between CAT and CHMP

European Medicines Agency decision

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance

Pharmacovigilance Working Party (PhVWP)

Changing practice to support service delivery

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Transcription:

Standard operating procedure Title: Early Notification System: procedure for advanced notification of emerging safety issues to EU regulatory network and international partners Status: PUBLIC Document no.: SOP/H/3346 Lead author Approver Effective date: 13-APR-11 Name: Malika Holleyman Name: Noël Wathion Review date: 13-APR-14 Signature: ON FILE Signature: ON FILE Supersedes: N/A Date: 19-JAN-11 Date: 11-APR-11 TrackWise record no.: 2822 1. Purpose The purpose of this standard operating procedure (SOP) is to describe the process for the Early Notification System (ENS). The purpose of the ENS is to notify the European Union (EU) regulatory network (European Medicines Agency [EMA], National Competent Authorities [NCAs] and the European Commission) and international partners of emerging safety issues for which regulatory action and communication are envisaged. Notification is given every month in advance of the Committee for Medicinal Products for Human Use (CHMP) meeting. Before the end of the CHMP meeting, the completed communication material is disseminated within the EU regulatory network and to international partners prior to publication on the EMA website. As part of the procedure, the Pharmacovigilance Working Party (PhVWP) prepares a table with outcome recommendations following each monthly meeting, which is disseminated within the EU regulatory network. 2. Scope This SOP applies to the Human Medicines Development and Evaluation Unit, the Patient Health Protection Unit and the Office of the Executive Director. 3. Responsibilities It is the responsibility of each Head of Sector to ensure that this procedure is adhered to within his or her sector. The responsibility for the execution of each step of this procedure is identified in the righthand column headed 9. Procedure. The Medical Information Sector is responsible for the co-ordination of the procedure. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

4. Changes since last revision New SOP. 5. Documents needed for this SOP The templates needed for this SOP can be found on the X: drive: X:\Templates\Others\H - Early notification templates folder. The templates for lines to take and press releases are available in Microsoft Word under File/New and can be found on the X: drive: X:\Templates\Filenew\Press. The templates for question-and-answer documents (Q&As) can be found on the X: drive: X:\Templates\Others\H - Q&A documents. The list of contacts (EU Regulatory network and international partners) is saved in Documentum\Docbases\EDMS\Operational Units\Human\Post\MIS\ Early Notification System & LTT\Contact lists. 6. Related documents SOP/EMA/0111 Preparation, dissemination and publication of safety-related EMA press releases and question-and-answer documents. SOP/H/3347 - Preparation of lines-to-take documents for use within the EU regulatory network to answer external queries in a consistent manner. WIN/H/3210 - Sending of lines to take and safety-related information to the European Union regulatory network and international partners. WIN/H/3234 Preparation of CHMP monthly report. Policy on European Medicines Agency communication on (emerging) safety related Issues for medicines for human use (EMA/170165/2010). European Medicines Agency Communication on (emerging) safety related issues for medicines for human use practical arrangements (EMA/785792/2009). 7. Definitions CHMP: Committee for Medicinal Products for Human Use D-ED-COM: Communications and Media EMA: European Medicines Agency EU: European Union ENS: Early Notification System LTT: Lines to take MedW: Medical writer NCA: National Competent Authority PhVWP: Pharmacovigilance Working Party SOP/H/3346, 13-APR-11 Page 2/7

: Assistant in the Medical Information Sector : Head of Medical Information Sector POM: Product oversight meeting PR: Press release PTL: Product team leader Q&A: Question-and-answer document Sec.: Secretariat SOP: Standard operating procedure TC: Teleconference SOP/H/3346, 13-APR-11 Page 3/7

8. Process map(s) / flow chart START Monday two weeks prior to CHMP to Tuesday prior to CHMP 1.Provide ENS template table to EMA staff for completion. 2. PTL to Identify safety issues. 3. PTL to complete the ENS table with identified safety issues. 4. to amend the ENS table. Tuesday prior to CHMP to Wednesday prior to CHMP 5. PTL to present the identified safety issue at the POM. 6. HoS P-MI to ensure for each issue that a decision is made on the need to communicate and which tools will be used. 7. HoS-P-MI to update ENS table with the information agreed during the POM. Wednesday Prior to CHMP 8. to circulate updated ENS table to the CHMP secretariat. 9. HoS-P-MI to present ENS table at TC with CHMP (Vice) Chair. Thursday prior to CHMP 10. HoS-P-MI to update ENS table. 11. PhVWP Sec. to provide with the PhVWP table. 12. to prepare and disseminate ENS and PhVWP tables (in accordance with WIN/H/3210). Go to step 13 SOP/H/3346, 13-APR-11 Page 4/7

From step 12 Wednesday during CHMP 13. In case of controversial issues, to inform the EU regulatory network (and international partners when necessary) of any change in communication tool or embargo time. 14. MedW/D-ED-COM to provide P- MI AST with final Q&A and/or PR. 15. to disseminate Q&A and/or PR (in accordance with WIN/H/3210). END SOP/H/3346, 13-APR-11 Page 5/7

9. Procedure Step Action Responsibility 1. Monday two weeks before the CHMP meeting: Prepare ENS table and send it by email to the relevant EMA staff for completion. The list of recipients and the e-mail template are saved on the X: drive: X:\Templates\Others\H - Early notification templates folder. 2. Identify safety issues that may require communication after the CHMP meeting (as proposed in the Policy on European Medicines Agency communication on (emerging) safety related Issues for medicines for human use (EMA/170165/2010)). As a guide, the following types of safety issues should be included: Suspension, withdrawal or revocation of a marketing authorisation for safety reasons; Start or finalisation of a community referral or review procedure initiated for safety reasons (e.g. article 5(3), 20, 31 or 107); New safety information such as new contraindications, warnings or undesirable effects; Supply shortages; Product defects that may lead to safety concerns; Restrictions of indication or reductions of dose; Any other emerging safety concerns that may give rise to media interest. PTL 3. Complete the ENS table with the identified safety issues before noon of Tuesday prior to the CHMP meeting. The ENS table is discussed during the POM that is scheduled for the afternoon of that day. PTL Tuesday prior to the CHMP meeting: 4. Ensure that the information for every product in the ENS table is complete in accordance with the template requirements. 5. Present the identified safety issue(s) for discussion during the POM. PTL 6. For every issue, ensure that a decision is made on whether there is a need to communicate or not. Agree on the communication tools (i.e. Q&A, PR, CHMP press release, CHMP monthly report or LTT) to be used in each case. If a Q&A or PR is to be prepared, follow SOP/EMA/0111. If LTT are to be prepared, follow SOP/H/3347. SOP/H/3346, 13-APR-11 Page 6/7

Step Action Responsibility For issues to be included in the CHMP monthly report, follow WIN/H/3234. 7. Update the ENS table with the information obtained during the meeting, including the embargo for publication. Wednesday prior to the CHMP meeting: 8. Supply the updated ENS table to the CHMP secretariat, for circulation to the CHMP Chair and Vice-Chair. Thursday prior to the CHMP meeting: 9. Present the ENS table during the teleconference with the CHMP Chair and Vice-Chair. 10. Implement any changes to the ENS table agreed during the teleconference with the Chair and Vice-Chair. 11. Provide with the PhVWP table with outcome recommendations following each monthly meeting by 12:00 noon for circulation. PhVWP Secretariat 12. Prepare and disseminate the ENS and PhVWP tables to the EU regulatory network and when applicable to international partners in accordance with WIN/H/3210. Wednesday during CHMP meeting: 13. In case of controversial issues during CHMP discussions, inform the EU regulatory network (and international partners if necessary) of any change in the communication plan (e.g. change in communication tool, change in embargo time, etc). 14. Provide with the locators of the final versions of all completed safety-related Q&As or LLT by 3:00pm. MedW Provide with the locators of the final versions of all completed safety-related PRs by 3:00pm. D-ED-COM 15. Disseminate PRs, Q&As and LTT to the EU regulatory network and when applicable to international partners in accordance with WIN/H/3210. 10. Records Original signed hard copies of cover notes are filed in the ENS master file. The electronic copies are saved in Documentum\Docbases\EDMS\Operational Units\Human\Post\MIS\Early Notification System & LTT\Faxes. Copies of all correspondence are also saved in Chrono H-MIS. SOP/H/3346, 13-APR-11 Page 7/7